Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Boston Scientific Corp. (NYSE:BSX)

Paying users zone. Data is hidden behind: .

  • Get 1-month access to Boston Scientific Corp. for $15.99, or

  • get full access to the entire website for at least 3 months from $49.99.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey

This is a one-time payment. There is no automatic renewal.

Price to FCFE (P/FCFE)

Intermediate level


Free Cash Flow to Equity (FCFE)

Boston Scientific Corp., FCFE calculation

US$ in millions

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Net income (loss)
Net noncash charges
Increase (decrease) in operating assets and liabilities, net of acquisitions
Cash provided by operating activities
Purchases of property, plant and equipment
Proceeds on disposals of property, plant and equipment
Proceeds from short-term borrowings, net of debt issuance costs
Net increase (decrease) in commercial paper
Proceeds from borrowings on credit facilities
Payments on borrowings from credit facilities
Payments on short-term borrowings
Payments on long-term borrowings and debt extinguishment costs
Proceeds from long-term borrowings, net of debt issuance costs
Free cash flow to equity (FCFE)

Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-24).

Item Description The company
FCFE Free cash flow to equity is the cash flow available to Boston Scientific Corp.’s equity holders after all operating expenses, interest, and principal payments have been paid and necessary investments in working and fixed capital have been made. Boston Scientific Corp.’s FCFE increased from 2017 to 2018 and from 2018 to 2019.

Price to FCFE Ratio, Current

Boston Scientific Corp., current P/FCFE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
No. shares of common stock outstanding
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in millions)
FCFE per share
Current share price (P)
Valuation Ratio
P/FCFE
Benchmarks
P/FCFE, Competitors1
Becton, Dickinson & Co.
Danaher Corp.
Intuitive Surgical Inc.
Medtronic PLC
Stryker Corp.
Thermo Fisher Scientific Inc.
UnitedHealth Group Inc.
P/FCFE, Sector
Health Care Equipment & Services
P/FCFE, Industry
Health Care

Based on: 10-K (filing date: 2020-02-25).

1 Click competitor name to see calculations.

If the company P/FCFE is lower then the P/FCFE of benchmark then company is relatively undervalued.
Otherwise, if the company P/FCFE is higher then the P/FCFE of benchmark then company is relatively overvalued.


Price to FCFE Ratio, Historical

Boston Scientific Corp., historical P/FCFE calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
No. shares of common stock outstanding1
Selected Financial Data (US$)
Free cash flow to equity (FCFE) (in millions)2
FCFE per share3
Share price1, 4
Valuation Ratio
P/FCFE5
Benchmarks
P/FCFE, Competitors6
Becton, Dickinson & Co.
Danaher Corp.
Intuitive Surgical Inc.
Medtronic PLC
Stryker Corp.
Thermo Fisher Scientific Inc.
UnitedHealth Group Inc.
P/FCFE, Sector
Health Care Equipment & Services
P/FCFE, Industry
Health Care

Based on: 10-K (filing date: 2020-02-25), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-23), 10-K (filing date: 2016-02-24).

1 Data adjusted for splits and stock dividends.

2 See details »

3 2019 Calculation
FCFE per share = FCFE ÷ No. shares of common stock outstanding
= ÷ =

4 Closing price as at the filing date of Boston Scientific Corp.’s Annual Report.

5 2019 Calculation
P/FCFE = Share price ÷ FCFE per share
= ÷ =

6 Click competitor name to see calculations.

Valuation ratio Description The company
P/FCFE Price to free cash flow to equity is cash valuation indicator of stockholders’ equity. Boston Scientific Corp.’s P/FCFE ratio increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.